HIV type 1 integrase inhibitors: From basic research to clinical implications

AIDS Reviews

Volumn 10, Issue 3, 2008, Pages 172-189

  Jagede, Oyebisi ^a   Babu, John ^b   Di Santo, Roberto ^c   McColl, Damian J ^d   Weber, Jan ^e   Quiñones Mateu, Miguel E ^e  

^a KENT STATE UNIVERSITY   (United States)

^b Panvirex LLC   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d GILEAD SCIENCES   (United States)

^e Quidel Corporation   (United States)

Author keywords

Drug resistance; HIV; Integrase inhibitors; Replicative fitness

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTIRETROVIRUS AGENT; ATAZANAVIR; BEVIRIMAT; BMS 707035; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; GENOMIC RNA; GSK 364735; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL RESISTANCE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CROSS RESISTANCE; DIARRHEA; DNA INTEGRATION; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME STRUCTURE; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; PHARMACOPHORE; PRURITUS; RECOMMENDED DRUG DOSE; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; SIDE EFFECT; SWEATING; TREATMENT DURATION; VIRION; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; TREATMENT OUTCOME; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 55049092459     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with HIV infection abd prior antiretroviral therapy. N Engl J Med. 1997;337:734-39.
2. 3. ACTG 320 Study Team. N Engl J Med. 1997;337:725-33.
3. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-6.
4. Lederman M er L, Mizell S, et al. Presence of an inducible HIV-1 latent reservoir during HAART. Proc Natl Acad Sci USA. 1997;94:13193-7.
5. Chun T, Davey R, Ostrowski M, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of HAART. Nat Med. 2000;6:757-61.
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on HAART. Science. 1997;278:1295-300.
7. Deeks S. Treatment of anti retroviral-drug-resistant HIV-1 infection. Lancet. 2003;362:2002-11.
8. Little S, Holte S, Routy J. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94.
9. Blankson J, Persaud D, Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002:53:557-93.
10. Saksena N, Potter S. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev. 2003;5:3-18.
11. Turner B, Summers M. Structural biology of HIV. J Mol Biol. 1999;285:1-32.
12. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-67.
13. Weber J. Piontkivska H, Quinones-Mateu M. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev. 2006,8:60-77.
14. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA. 2003;100:13555-60.
15. Brown P, Bowerman B, Varmus H, Bishop H. Correct integration of retroviral DNA in vitro. Cell. 2007;49:347-56.
16. Barbosa P, Charneau P, Dumey N, Clavel F. Kinetic analysis of HIV-1 early replicative steps in a co-culture system. AIDS Res Hum Retroviruses. 1994;10:53-9.
17. Pauza C, David T, Mckechnie P, at al. 2-LTR circular viral DNA as a marker for HIV-1 infection in vivo. Virology. 1994;205:470-8.
18. Shin C, Taddeo B, Haseltine W, Farnet C. Genetic analysis of the HIV-1 integrase protein. J Virol. 1994;68:1633-42.
19. Bushman F, Fujiwara T, Craigie R. Retroviral DNA integration directed by HIV integration protein in vitro. Science. 1990;249:1555-8.
20. Goff SP. Genetics of retroviral integration. Annu Rev Genet. 1992;26:527-44.
21. Vink C, Plasterk PH. The HIV integrase protein. Trends Genet. 1993;9:433-8.
22. Flint S, Enquist L, Enquist L, Skalka A. Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses, 2nd Edition. ASM Press 2003.
23. Pommier Y, Pilon A, Bajaj K, Mazumdar A, Neamati N. HIV-1 integrase as a target for antiviral drugs. Antiviral Chem Chemother. 2007;8:463-83.
24. Ellison V, Garton J, Vincent K, Brown P. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J Biol Chem. 1995;270:3320-6.
25. Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 1993;12:3269-75.
26. Goldgur Y, Craigie R, Cohen G, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA. 1999;96:13040-3.
27. Lubkowski J, Yang F, Alexandratos J, et al. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc Natl Acad Sci USA. 1998;95:4831-6.
28. Chen J, Krucinski J, Miercke L, et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA. 2000;97:8233-8.
29. Molteni V, Greenwald J, Rhodes D, et al. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr D Biol Crystallogr. 2001;57:536-44.
30. Burke C, Sanyal G, Bruner MW, et al. Structural implications of spectroscopic characterization of a putative zinc finger peptice from HIV-1 integrase. J Biol Chem. 1992;267:9639-44.
31. Cai M, Zheng R, Caffrey M. Craigie R, Clore GM, Gronenborn A. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol. 1997;4:567-77.
32. Zheng R, Jenkins T, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci USA. 1996;93:13659-64.
33. Davies D, Goryshin I, Reznikoff W, Rayment I. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science. 2000;289:77-85.
34. Dyda F, Hickman A, Jenkins T, Engelman A, Craigie R, Davies D. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotide transferases. Science. 1994;266:1981-6.
35. Bushman F, Engelman A, Palmer I. Wingfield P, Craigie R. Domains of the integrase protein of HIV-1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci USA. 1993;90:3428-32.
36. Katayanagi K, Okumura M, Morikawa K. Crystal structure of E. coli RNase HI in complex with Mg2+ at 2.8 A resolution: proof for a single Mg(2+)-binding site. Proteins. 1993;17:337-46.
37. Rice P, Craigie R, Davies D. Retroviral integrases and their cousins. Curr Opin Struct Biol. 1996;6:76-83.
38. Rice P, Mizuuchi K. Structure of the bacteriophage Mu transposase core: a common structural motif for DNA transposition and retroviral integration. Cell. 1995,82:209-20.
39. Pommier Y, Johnson A, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov. 2005;4:236-48.
40. Engelman A, Craigie R. Identification of conserved amino acid residues critical for HIV-1 integrase function in vitro. J Virol. 1992;66:6361-9.
41. Drelich M, Wilhelm R, Mous J. Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. Virology. 1992;188:459-68.
42. Kulkosky J, Jones K, Katz R, Mack J, Skalka A. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol. 1992;12:2331-8.
43. van Gent D, Oude Groeneger A, Plasterk R. Identification of amino acids in HIV-2 integrase involved in site-specific hydrolysis and alcolholysis of viral DNA termini. Nucleic Acids Res. 1993;21:3373-7.
44. Vink C, Oude Groeneger A, Plasterk R. Identification of the catalytic and DNA-binding region of the HIV-1 integrase protein. Nucleic Acids Res. 1993;21:1419-25.
45. Colicelli J, Goff S. Sequence and spacing requirements of a retrovirus integration site. J Mol Biol. 1988;199:47-59.
46. LaFemina R, Callahan P, Cordingley M. Substrate specificity of recombinant HIV integrase protein. J Virol. 1991;65:5624-30.
47. Sherman P, Fyfe J. HIV integration protein expressed in E. coli possesses selective DNA cleaving activity. Proc Natl Acad Sci USA. 1990; 87:5119-23.
48. Miller M, Farnet C, Bushman F. HIV-1 preintegration complexes: studies of organization and composition. J Virol. 1997;71:5382-90.
49. Bukrinsky M, Sharova N, McDonald T, Pushkarskaya T, Tarpley W, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of HIV-1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA. 1993;90:6125-9.
50. Lin C, Engelman A. The barrier-to-autointegration factor is a component of functional HIV-1 preintegration complexes. J Virol. 2003;77:5030-6.
51. Kalpana G, Marmon S, Wang W, Crabtree G, Goff S. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 1994;266:2002-6.
52. Farnet C, Bushman F. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell. 1997; 88:483-92.
53. Gao K, Gorelick R, Johnson D, Bushman F. Cofactors for HIV-1 cDNA integration in vitro. J Virol. 2003;77:1598-603.
54. Li L, Yoder K, Hansen M, Olvera J, Miller M, Bushman F. Retroviral cDNA integration: stimulation by HMG 1 family proteins. J Virol. 2000;74:10965-74.
55. Maertens G, Cherepanov P, Pluymers W, et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem. 2003;278:33528-39.
56. Cherepanov P, Maertens G, Proost P, et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem. 2003;278:372-81.
57. Johnson A, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem. 2004;41059-77.
58. Leavitt A, Rose R, Varmus H. Both substrate and target oligonucleotide sequences affect in vitro integration mediated by HIV-1 integrase protein produced in Saccharomyces cerevisiae. J Virol. 1992;66:2359-68.
59. Yoder K, Bushman F. Repair of gaps in retroviral DNA integration intermediates. J Virol. 2000;74:11191-200.
60. De Clercq E. New anti-HIV agents and targets. Med Res Rev. 2002;22:531-65.
61. Hazuda D, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646-50.
62. Mekouar K, Mouscadet J, Desmaele D, et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem. 1998;41:2846-57.
63. Hong H, Neamati N, Wang S, et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem. 1997;40:930-6.
64. Zhao H, Neamati N, Sunder S, et al. Hydrazide-containing inhibitors of HIV-1 integrase. J Med Chem. 1997;40:937-41.
65. Neamati N, Hong H, Owen JM, et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J Med Chem. 1998;41:3202-9.
66. Nicklaus MC, Neamati N, Hong H, et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem. 1997;40:920-9.
67. Chen I, Neamati N, Nicklaus M, et al. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Bioorg Med Chem. 2000;8:2385-98.
68. Zouhiri F, Mouscadet J, Mekouar K, et al. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem. 2000;43:1533-40.
69. Marchand C, Zhang X, Pais G. et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem. 2002; 277:12596-603.
70. Zhang X, Godwin C, Pais G, et al. Azido-Containing aryl B-Diketo acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett. 2003;13:1215-19.
71. Grobler J, Stillmock K, Hu B, et al, Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes Proc Natl Acad Sci USA. 2002; 99:6661-6.
72. Marchand C, Johnson A, Karki R, et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Vol Pharmacol. 2003;64:600-9.
73. Wallace T, Gamba-Vitalo C, Loveday K, Cossum P. Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide. Toxicol Sci. 2000;53:63-70.
74. Wallace T, Bazemore S, Holm K, et al. Pharmacokinetics and distribution of a 33P-labeled anti-HIV oligonucleotide (AR177) after single- and multiple-dose intravenous administration to rats. J Pharmacol Exp Ther. 1997;280:1480-8.
75. Smart T. The first integrase inhibitor. GMHC Treat Issues. 1996;10:8-9.
76. Este J, Cabrera C, Schols D. et al. HIV glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol. 1998;53:340-5.
77. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Invest Drugs. 2003;4:206-9.
78. Little S, Drusano G, Schooley R, et al. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients. Proceedings of the 12th CROI, Boston, 2005:161.
79. Markowitz M, Morales-Ramirez J, Nguyen B, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-15.
80. Markowitz M, Nguyen B, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. XVI International AIDS Conference, Toronto, Canada. 2006:THLB0214.
81. Grinsztejn B, Nguyen B, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, Proceedings of the 13th CROI, Denver. 2006:159LB.
82. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Proceedings of the 14th CROI, Los Angeles. 2007:105aLB.
83. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Proceedings of the 14th CROI, Los Angeles. 2007:105bLB.
84. Steigbigel R, Kumar P, Eron J, et al. 48-week results from BENCHMRK-2, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV. CROI, Boston. 2008:357.
85. Cooper D Gatell J, Rockstroh J, et al. 48-week results from BENCH-MRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1. CROI, Boston. 2008:357.
86. Cooper D, Steigbigel R, Gatell J, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-65.
87. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. IN Engl J Med. 2008;359:339-54.
88. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem. 2006;49:1506-8.
89. Kawaguchi I, Ishikawa T, Ishibashi M, Irie S, Kakee A. Safety, pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel integrase inhibitor, in healthy volunteers. Proceedings of the 13th CROI, Denver. 2006:580.
90. Kearney B, Mathias A, Zhong L. Pharmacokinetics/pharmacodynamics of GS-9137, an HIV integrase inhibitor in treatment-naive and experienced patients. Proceedings of the 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal. 2006:73.
91. Mathias A, Jain A, Hui J. Shen G, Kearney B. Pharmacokinetic characterization of GS-9137 and HIV integrase inhibitor dosed with ritonavir. Proceedings of the 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal. 2006:75.
92. DeJesus E, Berger D, Markowitz M, et al. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naive and experienced patients. Proceedings of the 13th CROI, Denver. 2006:160LB.
93. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5.
94. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. Proceedings of the 14th CROI, Los Angeles, 2007:143LB.
95. Zolopa A, Lampiris H, Blick G, et al. The HIV integrase inhibitor elvite-gravir (EVG/r) has a potent and durable antiretroviral activity in treatment-experienced patients with active optimized background therapy. 47th ICAAC. 2007.
96. Reddy Y, Min S, Borland J, et al. Safety and pharmacokinetics of GSK364735, a HIV-1 integrase inhibitor, following single and repeated administration in healthy adult subjects. Antimicrob Agents Chemother. 2007;51:4284-9.
97. Fikkert V, Van Maele B, Vercammen J, et al. Development of resistance against diketo derivatives of HIV-1 by progressive accumulation of integrase mutations. J Virol. 2003;77:11459-70.
98. Hazuda D, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646-50.
99. Hazuda D, Anthony N, Gómez R, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA. 2004;101:11233-8.
100. Hazuda D, Young S, Guare J, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528-32.
101. Fikkert V, Hombrouck A, Van Remoortel B, et al. Multiple mutations in HIV-1 integrase confer resistance to the clinical trial drug S-1360. AIDS. 2004;18:2019-28.
102. Hombrouck A, Voet A, Van Remoortel B, et al. Mutations in HIV-1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother. 2008;52:2069-78.
103. Hombrouck A, Van Remoortel B, Michiels M, et al. Preclinical evaluation of 1H-benzylindole derivatives as novel HIV integrase strand transfer inhibitors. Antimicrob Agents Chemother. 2008;52:2861-9.
104. Yoshinaga T, Nakahara K, Kobayashi M, et al. Characterization of resistance properties of a new integrase inhibitor S/GSK364735. CROI, Boston. 2008:387.
105. Witmer M, Danovich R, Ke Y, et al. In vitro resistance selection studies using raltegravir: a novel inhibitor of HIV-1 integrase. 8th Annual Symposium on Antiviral Drug Resistance, Richmond, USA. 2007.
106. Goethals O, Clayton R, Wagemans E, et al. Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
107. Hazuda D, Miller M, Nguyen B, Zhao J, P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. Antiviral Therapy. 2007;12:S10.
108. Miller M, Danovich R, Ke Y, et al. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005, a phase 2 study in treatment experienced patients. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
109. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
110. Hatano H, Lampiris H, Huang W, et al. Virologic and immunologic outcomes in a cohort of subjects failing integrase inhibitors. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
111. Katlama C, Caby F, Schneider L, et al. Virologic evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
112. Ceccherini-Silberstein F, Armenia D, D'Arrigo R, et al. Virologic response and resistance in multi-experienced patients treated with raltegravir. XVII International HIV Drug Resistance Workshop, Sitges. Spain. 2008.
113. Da Silva D, Pellegrin I. Anies G, et al. Mutational patterns in the HIV-1 integrase related to virologic failures on raltegravir-containing regimens. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
114. Markowitz M, Nguyen B, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-33.
115. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th CROI 2007; Program and abstracts; Los Angeles, Calif. 2007:Oral 105aLB.
116. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th CROI; Program and abstracts. Los Angeles 2007:Oral 105bLB.
117. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52:1351-8.
118. Charpentier C, Karmochkine M, Laureillard D, et al. Drug resistance profiles of HIV integrase gene in patients failing raltegravir-slavage therapy. 6th European HIV Drug Resistance Workshop, Budapest, Hungary. 2008.
119. Goodman D, Hluhanich R, Waters J. et al. Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increase resistance. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008.
120. Wai J, Fisher T, Embrey M, et al. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles. CROI, Los Angeles. 2007:96.
121. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel HIV integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82:764-74.
122. Ren C, May S, Milletti T, Bedard J. In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1. Anti-viral Therapy. 2007;12:S3.
123. Jones G, Ledford R, Yu F, et al. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor GS-9137 (JTK-303). CROI, Los Angeles. 2007.
124. Garvey E, Johns B, Gartland M, et al. The naphthyridinone GSK364735 is a novel, potent HIV-1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008;52:901-8.
125. McColl D, Fransen S, Gupta S, et al. Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy. 2007;12:S11.
126. Hackett J, Harris B, Holzmayer V, et al. Naturally occurring polymorphisms in HIV-1 group M, N, and O integrase: implications for integrase inhibitors. CROI, Boston. 2008:392.
127. Roquebert B, Famond F, Collin G, et al. Phenotypic susceptibility in vitro to raltegravir and elvitegravir and polymorphism of the integrase gene of HIV-2 clinical isolates. CROI, Boston. 2008:398.
128. - integrase gene and mutations associated with integrase inhibitor resistance, Antivir Ther. 2007;12:563-70.
129. Leoz M, Depatureaux A, Vassiere A, et al. Integrase polymorphism and HIV-1 group O diversity. AIDS. 2008;22:1239-43.
130. Fikkert V, Van Maele B, Vercammen J, et al. Development of resistance against diketo derivatives of HlV-1 by progressive accumulation of integrase mutations. J Virol. 2003;77:11459-70.
131. Fikkert V, Hombrouck A, Van Remoortel B, et al. Multiple mutations in HIV-1 integrase confer resistance to the clinical trial drug S-1360. AIDS. 2004; 18:2019-28.
132. Quinones-Mateu ME, Arts EJ. Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microb Immunol. 2006;299:83-140.
133. Quinones-Mateu ME, Arts EJ. HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, et al. eds. HIV Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2001:134-70.
134. Malet I, Delelis O, Valentin M, et al. Biochemical characterization of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518). Antiviral Therapy. 2007;12:S9.
135. Chun T, Justement J, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007;195:1762-4.
136. Finzi D, Blankson J, Siliciano J, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-17.
137. Quinn T, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science. 2005;308:1582-3.
138. Madan R, Keller M, Herold B. Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr Opin Infect Dis. 2006;19:49-54.
139. Terrazas-Aranda K, Van Herrewege Y, Hazuda D, et al. HIV-1 integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother. 2008; 52:2544-54.
140. Goldgur Y, Dyda F, Hickman A, Jenkins T, Craigie R, Davies D. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Aced Sci USA. 1998;95:9150-4.